Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Ransart – page 46

1 856 clinical trials in Ransart, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Ransart at a glance
1 856
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 856 trials in Ransart

Open in trial search

Study Comparing Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone with Ciltacabtagene Autoleucel or Stem Cell Transplant for Newly Diagnosed Multiple Myeloma Patients

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Emn Trial Office S.r.l. Impresa Sociale

IgA nephropathy

Recruiting

Long-Term Safety Study of Iptacopan for Adults with IgA Nephropathy After Completing a Previous Study, Including ACE Inhibitors and ARBs Drug Combination

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Iptacopan
  • Sponsor:Novartis Pharma AG

Study on the Safety and Effects of Tolvaptan for Children with Autosomal Recessive Polycystic Kidney Disease (ARPKD)

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Tolvaptan
  • Sponsor:Otsuka Pharmaceutical Development & Commercialization Inc.

Neoplasm

Recruiting

Study of Patritumab Deruxtecan for Patients with Advanced or Metastatic Solid Tumors

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Patritumab Deruxtecan
  • Sponsor:Daiichi Sankyo Inc.

Study Comparing Elranatamab to Drug Combinations for Patients with Relapsed/Refractory Multiple Myeloma After Anti-CD38 Therapy

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Pfizer Inc.

Study on Long-Term Safety of Tolebrutinib and Teriflunomide for Patients with Multiple Sclerosis

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Teriflunomide
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study on the Effectiveness of 2LPAPI with Interferon Alfa in Clearing Genital HPV Infections in Patients

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Ciclosporin A
  • Sponsor:Labo'Life Belgium

Study Comparing MK-2870 and Pembrolizumab with Chemotherapy for Patients with Advanced Hormone Receptor Positive Breast Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Merck Sharp & Dohme LLC

Study on Lisaftoclax and Acalabrutinib for Patients with Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:Ascentage Pharma Group Inc.

Study on Stiripentol for Patients Aged 6 and Older with Primary Hyperoxaluria Types 1, 2, or 3

Registered drug
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Stiripentol
  • Sponsor:Biocodex

Study of Epoetin Alfa for Critically Ill Patients with Traumatic Injury

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Epoetin Alfa
  • Sponsor:University College Dublin

Penile cancer

Recruiting

Study on the Effectiveness of Carboplatin, Paclitaxel, and Pembrolizumab for Patients with Advanced Penile Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Ransart

What the registry says about research in the country

01 Gastroenterology Research

Clinical trials focusing on optimizing treatment strategies for patients with functional dyspepsia and related gastrointestinal conditions. The research explores innovative approaches to medication management, particularly in the context of proton pump inhibitors (PPIs) usage.

  • Medication De-prescribing Strategies
  • Gastrointestinal Health Management
  • Treatment Optimization Studies

This primary care research evaluates different therapeutic approaches for managing heartburn and reflux symptoms, with a particular focus on developing evidence-based deprescribing protocols.

02 Primary Care Innovation

Investigation into novel treatment alternatives for long-term medication management, comparing on-demand therapy approaches with traditional treatment methods in primary care settings.

  • Alternative Treatment Strategies
  • Patient-Centered Care
  • Chronic Medication Management

The research aims to establish more effective and patient-friendly approaches to long-term medication use in primary care practice.

03 Therapeutic Alternatives

Evaluation of alginate-based treatments as alternative therapeutic options for gastrointestinal conditions, focusing on their potential role in medication transition strategies.

  • Comparative Effectiveness Research
  • Alternative Medicine Approaches
  • Treatment Transition Protocols

This research explores the efficacy of different therapeutic alternatives in managing common gastrointestinal symptoms while reducing dependency on traditional medications.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.